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Abstract
Breast cancer is the most common cancer in Western women and while its precise etiology is unknown, environmental
factors are thought to play a role. The organochlorine pesticide dieldrin is a persistent environmental toxicant thought to
increase the risk of breast cancer and reduce survival in the human population. The objective of this study was to define the
effect of developmental exposure to environmentally relevant concentrations of dieldrin, on mammary tumor development
in the offspring. Sexually mature FVB-MMTV/neu female mice were treated with vehicle (corn oil), or dieldrin (0.45, 2.25, and
4.5 mg/g body weight) daily by gavage for 5 days prior to mating and then once weekly throughout gestation and lactation
until weaning. Dieldrin concentrations were selected to produce serum levels representative of human background body
burdens, occupational exposure, and overt toxicity. Treatment had no effect on litter size, birth weight or the number of
pups surviving to weaning. The highest dose of dieldrin significantly increased the total tumor burden and the volume and
number of tumors found in the thoracic mammary glands. Increased mRNA and protein expression of the neurotrophin
BDNF and its receptor TrkB was increased in tumors from the offspring of dieldrin treated dams. This study indicates that
developmental exposure to the environmental contaminant dieldrin causes increased tumor burden in genetically
predisposed mice. Dieldrin exposure also altered the expression of BNDF and TrkB, novel modulators of cancer
pathogenesis.
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Introduction
Breast cancer is the most prevalent cancer in women, and
although the incidence varies with age, geography, ethnicity and
socioeconomic status, the lifetime risk of developing breast cancer
is 1 in 9, with 1 in 28 women expected to die from breast cancer
[1,2]. The geographic disparities in rates of breast cancer taken
together with studies of twins and migrants have yielded
compelling evidence that environmental factors play an important
role in the pathobiology of breast cancer [3–5]. Indeed, it is
thought that as much as 60% of breast cancer has an
environmental etiology [4,6], with strong toxicological evidence
linking a number of ubiquitous environmental contaminants to
breast cancer based on their ability to interact with or disrupt
hormone signalling pathways or alter mammary gland develop-
ment, thus altering susceptibility to mammary carcinogenesis
[7,8].
Of the environmental toxicants linked to breast cancer, dieldrin
is of particular interest owing to evidence of human exposure and
association with increased breast cancer rate and decreased
survival in women with the highest exposures [9–11]. However
the epidemiological literature is equivocal and mechanisms poorly
defined. A large prospective study in a Danish population found a
two-fold increased risk of developing breast cancer (adjusted odds
ratio 2.05 [95% CI 1.17–3.57]) in women with the highest dieldrin
exposure [10] with poorer overall survival and increased mortality
in breast cancer patients (RR, 2.61 [95% CI 0.97–7.01]) [9].
While this positive association was not observed in several smaller
studies [12,13], the strong statistical correlation observed in the
Danish studies taken together with results of animal studies
demonstrating that dieldrin alters mammary gland development
following developmental exposure [14], indicates the need to
further investigate this association. Dieldrin is an organochlorine
pesticide whose use was banned in North America over twenty
years ago, but it is still widely detectable within the domestic and
imported food supply [15]. Detectable levels of dieldrin are
reported in over 90% of the human population in serum, adipose
tissues and breast milk [16,17] with an estimated mean daily intake
of 0.5 mg/day [18,19] leading to human burdens of 117–289 ppb
[17,20]. Thus while epidemiological evidence for an association
between dieldrin and breast cancer is not conclusive, existing
evidence does indicate a cause for concern and highlights the need
to understand the potential role of dieldrin in breast cancer
pathogenesis, particularly given the long natural history of breast
cancer and ongoing worldwide exposure. Moreover, adequate
study of toxicant exposures during critical windows of mammary
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environmental toxicants in developing mammary structures and
that dieldrin readily crosses the placental barrier and is excreted in
breast milk leading to its accumulation in fetal and neonatal
adipose tissues including the mammary glands [21–23].
The ability of dieldrin to act as a xenoestrogen has been
proposed to underlie its ability to alter mammary carcinogenesis
and associated mortality [10,24], and is based largely on its ability
to increase proliferation in estrogen receptor-a (ER-a) positive
MCF-7 breast cancer cells [25]. However, dieldrin is a weak
estrogen, with 10
26 the potency of estradiol making it likely that
dieldrin acts via additional mechanisms [24]. Indeed dieldrin has
been shown to activate alternative estrogen pathways mediated by
ERb and GPR30. We have previously demonstrated dieldrin
increased attachment-independent survival in ER-a negative
breast cancer cells [26] supporting the notion that dieldrin acts
via pathways independent of traditional ER-a signaling.
We hypothesized that dieldrin modulates breast cancer
pathogenesis by altering expression of novel growth factors
thought to be involved in cancer progression. Specifically we
hypothesized that expression of the neurotrophins and their
cognate receptors is increased by dieldrin exposure. The
neurotrophin growth factors and their receptors have recently
been shown to play a role in mammary carcinomas as well as
several human malignancies including pancreatic and pulmonary
carcinoma [27–29]. The neurotrophins include nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF), neuro-
trophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5). While the
neurotrophins share a common low affinity receptor (p75NTR),
they also signal via three high affinity tyrosine kinase receptors
(Trks); NGF preferentially activates TrkA, BDNF and NT-4/5
prefer TrkB and NT-3 preferentially binds TrkC. Although
classically considered to be neuronal growth factors promoting
neuronal survival and differentiation, the neurotrophins and their
receptors are widely expressed in non-neuronal tissues [30].
Increased neurotrophin/neurotrophin receptor expression has
recently been demonstrated in mammary carcinoma [26,31–33],
where they are thought to play a role in survival and proliferation
of cancer cells [29,34].
A major limitation of human studies is the inability to control
for exposure, latency and confounders, therefore well designed
animal studies are essential for understanding the relationship
between exposure and altered cancer pathogenesis. However,
most contemporary animal studies fail to account for critical
windows of exposure, and relevant concentrations of test chemicals
representative of human exposure. Moreover, we propose that
testing on a background of risk may yield results of greater
relevance to human health.
In this study we examined the effect of developmental and
lactational exposure to dieldrin in a transgenic mouse model of
spontaneous mammary tumor formation. In this model the neu
oncogene, homologous to the human oncogene ErbB2 (Her2/neu),
under the control of the mouse mammary tumor virus long
terminal repeat (MMTV) promoter which is active throughout
mammary development, leads to the overexpression of constitu-
tively active oncogenic neu [35]. The c-neu gene encodes Erb-B2, a
trans-membrane glycoprotein (185 kDa) with tyrosine kinase
activity closely related to epidermal growth factor receptor (EGFR)
[36], and is overexpressed in twenty to thirty percent of primary
human breast cancers [37]. In this model, mice develop
spontaneous adenocarcinomas after a short latency period and
are a good model for human breast cancer [35]. In this study we
tested whether gestational and lactational exposure to environ-
mentally relevant concentrations of dieldrin altered the formation
of mammary tumors and whether the resulting mammary tumors
showed altered expression of the neurotrophins and their
receptors. The findings of this study support a role for dieldrin
as a promoter of breast cancer pathogenesis and activation of the
neurotrophin signalling pathway thought to be important in
mammary cancer pathogenesis.
Results
Pregnancy rate was significantly reduced by the highest dose of
dieldrin (4.5 mg/g BW) with fewer than 50% of females becoming
pregnant in this treatment group with no effect observed in the
lower dose treatment groups (Table S1). Despite this reduction in
pregnancy rate, dieldrin treatment had no effect on the sex ratio or
number of viable pups at delivery, nor on the number of male or
female pups alive at postnatal day 7 or at weaning (Table S1).
Furthermore, dieldrin showed no signs of general toxicity, as
assessed by body weight, posture, coat, lacrimation and startle
response. Body weight was affected by low dose dieldrin (0.45 mg/
g) with a modest increase in postnatal body weight from weeks 1–3
after which body weight did not differ from control for the
remaining 19 weeks (Figure 1). Mice treated with the highest dose
of dieldrin demonstrated significantly increased body weights from
week 11 and continuing until sacrifice at 22 weeks when mean
body weight differed by over 6 g (Control 23.662.59 g compared
to dieldrin 4.5, 29.863.77 g) (Figure 1). Liver and kidney weight
measured at necropsy did not reveal any effect of dieldrin
treatment on organ weight when calculated as a percentage of
body weight (data not shown).
At sacrifice .90% of all mice had palpable mammary tumors,
with tumors in the thoracic mammary glands being more
prevalent than inguinal tumors (Table 1). The total tumor burden
per mouse was significantly increased by dieldrin 4.5 mg/g
treatment compared to control (Table 1) with treated mice
burdened with 65% more tumors. The highest dose of dieldrin led
to both an increased number of thoracic tumors per mouse and an
increased volume of incident tumors. In contrast, the mean
number of inguinal tumors was not significantly altered, and the
resulting volume of incident tumors was significantly decreased in
the inguinal compartment for the dieldrin 4.5 mg/g treated mice.
No significant changes in tumor number or volume were observed
in the dieldrin 0.45 and 2.25 mg/g treatment groups. Preliminary
assessment of tumors arising in ovaries and liver assessed by
histology revealed an increased incidence of ovarian tumors in
dieldrin 2.25 mg/g (7.5%) and 4.5 mg/g (10.5%) versus control
(2.6%). Increased liver tumors were also found in both higher dose
dieldrin groups, with liver tumors occurring in 18.8% of dieldrin
2.25 mg/g treated mice and 52.6% of dieldrin 4.5 mg/g treated
mice compared with 11.8% of control mice.
Dieldrin treatment altered the expression profile of the
neurotrophins and the neurotrophin receptors in mammary
tumors. Based on quantitative RT-PCR, mRNA expression of
the TrkA ligand NGF was unaffected by dieldrin treatment
(Figure 2). In contrast, the TkrB ligand, BDNF was significantly
increased by 2.25 and 4.5 mg/g dieldrin treatment (Figure 2).
Expression of TrkA mRNA was reduced by dieldrin; a significant
reduction was observed in the lowest dose group while a trend
towards decreased expression was observed in the other dieldrin
treatment groups (Figure 3). In contrast, TrkB mRNA was
significantly increased in a dose-dependent manner in all three
dieldrin treatment groups (Figure 3). Expression of the low affinity
receptor p75NTR was unaffected by dieldrin treatment (Figure 3).
Increased TrkB and BDNF protein expression in tumors from
dieldrin treated animals was confirmed by Western blot (Figure 4).
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within mammary tumors and the mammary gland, immunohis-
tochemistry was performed on thoracic mammary glands
containing tumors (Figure 5). Figure 5A demonstrates the solid
nature of a typical epithelial adenocarcinoma-like tumors in the
mammary gland, characterized by prominent nuclei with little
cytoplasm. Within the normal structures of the mammary gland,
TrkB protein was present in myoepithelial cells adjacent to the
tumors as well as in the surrounding stroma (Figure 5A).
Mammary tumors expressing TrkB demonstrated a distinct
pattern of positive staining where cells on the outermost edges of
the tumor were more intensely stained than the interior of the
tumor (Figure 5B). TrkB-positive stroma adjacent to the TrkB
positive tumors was also noted (Figure 5B) as well as TrkB-positive
gland innervation (Figure 5C).
Discussion
Although dieldrin has been hypothesized to contribute to breast
cancer incidence and associated mortality, the mechanisms for this
observation have not been adequately addressed, nor has the
contribution of developmental exposure been examined. The
present study was designed to examine the ability of developmen-
tal and lactational exposure to dieldrin to alter mammary
tumorigenesis in a model of spontaneous mammary tumor
formation. This study demonstrates that dieldrin increases the
formation of mammary tumors and alters the expression profile of
neurotrophins/neurotrophin receptors in resulting tumors. While
a role for dieldrin in tumor initiation remains to be established, this
study supports the hypothesis that dieldrin exposure during critical
windows of development against a background of risk increases
mammary tumor development.
Dieldrin administration did not result in any signs of general
toxicity in the dams or offspring, although the pregnancy rate in
the high dose cohort was significantly reduced with only half of the
females achieving pregnancy. In mice, dieldrin was previously
found to reduce pregnancy rates although smaller litter size was a
more common consequence of exposure [38]. In contrast, we did
not observe any alterations in litter size, sex ratio or pup survival.
Although pups did not differ in birth weight, the high dose dieldrin
group demonstrated an increase in body weight at 11 weeks that
continued until sacrifice at 22 weeks. This increase in body weight
led to a final mean difference of 6 g/animal (compared to control)
at sacrifice. We believe that this increased body weight is a
consequence of the increased volume (and associated mass) of the
mammary tumors occurring in this group. Although the two lower
dieldrin dose groups did not alter total tumor development, the
Figure 1. Mean body weight. Mean body weight (g) of mice exposed to either the vehicle (solid square dashed line) or dieldrin 0.45 mg/g BW
(hollow square dashed line), dieldrin 2.25 mg/g BW (hollow square, solid line) and dieldrin 4.5 mg/g BW (solid square, solid line) throughout gestation
and lactation. Although there we no differences in body weight between groups at birth, low dose dieldrin (0.45 mg/g BW) caused a modest increase
in body weight from weeks 1 through 3 after which bodyweight did not differ from control. Dieldrin 4.5 mg/g BW increased body weight at 11 weeks
continuing until sacrifice at 22 weeks. Data are presented as the mean6(SEM). Data analyzed by ANOVA, * p,0.05 compared to vehicle control.
doi:10.1371/journal.pone.0004303.g001
Table 1. Tumor number and volume of offspring at sacrifice (22 weeks).
n Total Number Inguinal Tumors Thoracic Tumors
Number Volume Number Volume
Vehicle 84 4.6260.60 0.7560.13 15.6166.33 3.8160.51 49.12616.09
Dieldrin 0.45 mg/g BW 79 4.8260.43 1.0060.15 8.6261.84 4.2460.41 45.55611.82
Dieldrin 2.25 mg/g BW 81 4.5460.43 0.7360.12 12.4165.54 3.8260.36 18.2865.85
Dieldrin 4.5 mg/g BW 19 7.5861.24* 1.2160.31 8.6862.31* 6.3761.06* 77.30635.49*
Data expressed as Mean6SEM and differences between treatment groups were determined by one way ANOVA and appropriate post hoc test. Differences with a
p,0.05 are indicated by a
*. n=number of mice/group, tumor volume expressed in mm
3.
doi:10.1371/journal.pone.0004303.t001
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tumors per animal (7.5861.24 vs. 4.6260.60). In all treatment
groups, tumors were more prevalent in the thoracic mammary
glands than those in the inguinal region and were also much larger
in this compartment. High dose dieldrin treatment resulted in
significantly more thoracic tumors per animal that were also
significantly larger compared to control, while the other dieldrin
treatment groups did not significantly alter incidence or size of
tumors. Interestingly, high dose dieldrin led to a decrease in
inguinal tumor volumes, although no reduction in tumor incidence
was observed. The size of the mammary fat pad at the inguinal
versus thoracic site may also explain this discrepancy, with more
room to accommodate tumor growth in the thoracic compart-
ment. As such, we do not interpret this finding to be a protective
effect since there was an increase in overall tumor burden and no
reduction in incidence at the inguinal site. Furthermore, treatment
with the two higher doses of dieldrin resulted in a dramatic
increase in ovarian and liver tumors, with nearly a five fold
increase in tumors in the dieldrin 4.5 treatment group compared
to control. These data reveal that dieldrin treatment not only
increases mammary tumorigenesis but tumorigenesis in ovary and
liver, both estrogen-responsive organs. Ongoing studies aim to
further elucidate the cause(s) of these extra-mammary tumors.
The role of novel growth factors in dieldrin-induced mammary
tumor promotion was investigated in this study, and focused on
expression changes in the neurotrophin/neurotrophin receptor
family. In the present study all resulting mammary tumors expressed
mRNA for the neurotrophins NGF and BDNF and neurotrophin
receptors TrkA, TrkB and p75
NTR. The neurotrophins and
neurotrophin receptors have recently been implicated as novel
mediators of carcinogenesis in many tissues. A role for the
neurotrophins and their receptors in mammary carcinogenesis has
previously been examined, and although the data are inconsistent,
they do support a role for altered expression of these factors in cancer
progression [33,34]. Furthermore, we demonstrate that the tumors
occurring in the dieldrin treated animals have an altered neurotro-
phin/receptor profile. More specifically, tumors occurring in animals
in the high dose dieldrin group show significantly increased levels of
Figure 2. Dieldrin increases expression of BDNF mRNA. Mammary tumors from mice treated with vehicle or dieldrin (0.45, 2.25 and 4.5 mg/g
BW) throughout gestation and lactation were processed for RNA extraction and cDNA prepared by reverse transcription. Induction of neurotrophin
mRNA (NGF and BDNF) was determined by real time quantitative PCR. Expression of GAPDH was used for normalization. Each data point is the mean
of at least 6 specimens6SEM. Data analyzed by ANOVA, * p,0.05 compared to vehicle control.
doi:10.1371/journal.pone.0004303.g002
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pathway. Immunohistochemical staining demonstrated TrkB protein
expression in tumor epithelial cells at the outer edges of tumors, as
well as adjacent stroma and glandular epithelium. Western
immunoblot confirmed the increased mRNA expression translated to
increased protein expression in mammary tumors with both TrkB
and BDNF expression increased in mammary tumors from dieldrin
treated mice. Increased expression of TrkB/BDNF may indicate
increased neo-neurogenesis, wherein tumors initiate their own
innervation by the release of neurotrophic factors [39]. Although
this hypothesis was not directly investigated in this study, our results
support increased tumor expression of at least one neurotrophin.
Increased TrkB protein expression was recently observed in breast
cancer specimens compared with normal breast tissue [26,33], and
Figure 3. Neurotrophin and neurotrophin receptor mRNA
expression in mammary tumors. Dieldrin increases expression of
TrkB mRNA. Mammary tumors from mice treated with vehicle or
dieldrin (0.45, 2.25 and 4.5 mg/g BW) throughout gestation and
lactation were processed for RNA extraction and cDNA prepared by
reverse transcription. Induction of neurotrophin receptor mRNA (TrkA,
TrkB and p75NTR) was determined by real time quantitative PCR.
Expression of GAPDH was used for normalization. Each data point is the
mean of at least 6 specimens6SEM. Data analyzed by ANOVA, * p,0.05,
**p,0.01 compared to vehicle control.
doi:10.1371/journal.pone.0004303.g003
Figure 4. TrkB and BDNF protein expression in mammary
tumors. Dieldrin treatment increases TrkB and BDNF protein expres-
sion in resulting mammary tumors measured by Western immunoblot.
Tumors were sonicated on ice followed by protein extraction,
electrophoresis and immunoprobing for TrkB, BDNF and GAPDH. Blots
representative of at least four independent experiments.
doi:10.1371/journal.pone.0004303.g004
Figure 5. TrkB expression in mammary glands and tumors. TrkB
protein expression in mammary glands and tumors. Immunohisto-
chemical staining of formalin fixed mammary glands containing tumors
demonstrates TrkB protein expression in both epithelial and stromal
compartments. (A) TrkB positive myoepithelial cells encapsulating a
TrkB-negative tumor (206). (B) TrkB positive tumors demonstrating
positivity at the outer edges of the tumor and positive adjacent stroma
(206). (C) TrkB positive mammary gland innervation (46). (D) Negative
control (206).
doi:10.1371/journal.pone.0004303.g005
Dieldrin Increases Tumors
PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e4303although a correlation with clinical outcomes was not assessed in
thesestudies,elevatedTrkBexpressioninneuroblastomaiscorrelated
with a chemo-resistant phenotype [40], with increased mortality in
Wilm’s tumor [41] and is a predictor of distant metastases and
prognosis in gastric cancer [42]. Signaling via the BDNF/TrkB
pathway stimulates pro-survival signals, resistance to anoikis and
altered cellular aggregation, all features of cancer cells and
prerequisites of metastases formation [43]. While the role of TrkB/
BDNF signaling in breast cancer is currently unknown, evidence
from other malignancies supports a role for this pathway in tumor
progression and clinical prognosis and thus merits further explora-
tion. Increased angiogenesis, invasiveness and suppression of anoikis
resulting from BDNF/TrkB signaling contributes to the aggressive
phenotype of neuroblastoma tumors and is a likely mechanism for
altered mammary tumorigenesis. The direct or indirect mechanisms
by which dieldrin treatment in our model leads to increased
expression of these factors in resulting mammary tumors is currently
unknown and under investigation. In general, it is also currently
unknown what factors regulate neurotrophin and neurotrophin
receptor expression in normal and malignant breast tissues.
Dieldrin treatment did not alter expression of p75
NTR mRNA in
mammary tumors although TrkA expression was decreased.
Previous studies examining p75
NTR and TrkA expression in
breast tissue and carcinoma have been conflicting, correlating
increased expression to both good and poor prognosis [44–46].
Our study implicates TrkB signaling in mammary carcinogenesis
which has not yet been adequately investigated particularly given
its importance in cell survival and resistance to anoikis.
The mechanisms mediating dieldrin-induced tumor promotion
in mammary carcinoma are currently unknown although several
consequences of dieldrin exposure are themselves implicated in
tumor promotion including activation of estrogen signaling
pathways, oxidative stress [47], and inhibition of intercellular
communication [48]. Activation of estrogen signalling pathways,
specifically via ERa has been the preferred hypothesis since
dieldrin is known to stimulate classical nuclear ERa-mediated
signaling, although weakly. Alternative estrogen-dependent path-
ways mediated by ERb or GPR30 are potential candidate
pathways since estrogen is known to interact with these receptors
and are currently under investigation.
The findings of this study implicate developmental exposure to
dieldrin in mammary tumor promotion. The trans-placental and
lactational transfer of dieldrin to offspring and bioaccumulation of
this persistent pesticide in mammary tissues is cause for concern
given that developing mammary structures are bathed in this
toxicant with diverse biological actions. This study supports the
epidemiological evidence for increased breast cancer and associ-
ated mortality in the human population with elevated dieldrin
levels via tumor promotion. Furthermore, we provide evidence for
altered neurotrophin/neurotrophin receptor expression in mam-
mary tumors with elevated BDNF/TrkB in mammary tissues and
tumors. The findings of this study support the roles of both dieldrin
and TrkB signaling in mammary carcinoma and elucidation of the
mechanism by which these factors influence breast cancer
pathogenesis will be important for understanding toxicant-
modulated carcinogenesis as well as for developing novel
therapeutic targets and preventative strategies.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Animal Research
Ethics Board at McMaster University, in accordance with the
guidelines of the Canadian Council for Animal Care.
Animals
Sexually mature female (n=117) and male (n=60) FVB/N-
TgMMTV-neu mice were purchased from a commercial breeder
(Charles River) and bred in house. Animals were pair housed in
polycarbonate cages at 2262uC and 50610% relative humidity
on a 12:12 h light:dark lighting schedule. To exclude or minimize
other exogenous sources of estrogenic agents, mice were provided
with certified phytoestrogen-free rodent diet (TD96155; Harlan
Teklad) and provided tap water ad libitum throughout the
experiment.
Breeding & Dosing
Female mice (8–10 weeks old) were housed with a male breeder
mouse and examined daily for evidence of a sperm plug. Once a
sperm plug was found the male mouse was removed and females
were housed individually and pregnancy rate in each treatment
group recorded. Day 1 of gestation was defined as the day a sperm
plug was found. Dams (n=29–30 per group) were randomly
assigned to one of four treatment groups and treated daily by
gavage for five days 2 weeks prior to mating and then once weekly
throughout lactation until weaning with vehicle (Corn Oil) or
dieldrin 0.45, 2.25, and 4.5 mg/g BW. Dieldrin doses were
selected based on our previous experiments demonstrating this
dosing strategy achieves tissue residue levels (10–30 ng/g)
representative of those measured in human tissues reflecting
background exposure [49]. At weaning (3 weeks), dams and male
pups were culled and female pups began weekly dosing by gavage
through 9 weeks of age. At 22 weeks all pups (n=271) were
anaesthetized with isoflurane and exsanguinated by cardiac
puncture. At birth, post natal day 7 and weaning, the number,
sex and weight of pups was recorded. Weight of female pups from
weaning to sacrifice was recorded weekly. At sacrifice liver and
kidneys were excised and wet weight recorded. Throughout the
experiment, dams and offspring were monitored visually for signs
of general toxicity including loss of body weight, hunched posture,
ruffled coat, lacrimation, porphyria and startle response.
Mammary Tumor Data
A midline incision was made along the spine and the skin
removed to preserve the mammary gland structure. Mammary
tumors were counted and volume calculated based on maximum
and minimum diameter of tumors measured by callipers. Thoracic
tumors were excised and preserved in RNA later (Sigma Chemical
Co. Mississauga, ON).
Histology and Immunohistochemistry
At the time of sacrifice, inguinal mammary glands, ovaries,
uterus, kidneys, and liver were removed, fixed in 4% formalde-
hyde solution, dehydrated, and paraffin embedded. Sections
(5 mm) were stained with hematoxylin and eosin (H&E) for
histological analysis or processed for immunohistochemistry.
Tumors arising in each location was assessed by a blinded
observer and confirmed by a certified pathologist. Immunohisto-
chemistry was performed using the Vectastain Elite ABC Kit
(Vector Laboratories, Burlingame, CA) following the supplied
instructions. Mammary gland sections were rehydrated and
subjected to antigen retrieval using a low pH citrate buffer at
37uC, quenched for endogenous peroxidase activity with 3%
H2O2 in methanol for 10 min at RT, and incubated at 4uC
overnight with a primary antibody against TrkB at 1:400 (Santa
Cruz Biothechnology, Santa Cruz, CA). Slides were counter-
stained with Mayer’s hematoxylin and negative controls run using
pre-immune serum and positive controls using brain sections.
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Thoracicmammarytumorswere processedforprotein extraction
by immersioninice-cold RIPA buffercontainingproteaseinhibitors
(protease inhibitor cocktail tablets, Roche Diagnostics, Manheim,
Germany) for 10 mins, and sonicated on ice. Extracts were then
clarified by centrifugation and the concentration of protein in the
supernatant determined by a Bradford microplate assay (BioRad,
Hercules, CA, USA). Samples (20 mg protein) in reducing loading
buffer were boiled and electrophoresed through 8% SDS-PAGE
gels (Pierce, Rockford, IL). Separated proteins were electroblotted
onto PVDF membrane (BioRad, Hercules, CA) and blocked in 5%
non-fat powdered milk/Tris-buffered saline/Tween 20 (TBST) for
1 h. Primary antibodies used were anti-TrkB, rabbit mAb 1:200
(Cell Signaling, Danvers, MA); anti-BDNF, 1:200 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) and anti-GAPDH, 1:5000
(Abcam, Cambridge, MA). Blots were incubated in primary
antibody overnight at 4uC then washed and incubated in secondary
antibody-HRP conjugates for 1 h at RT (goat anti-rabbit at 1:5000;
Amersham Biosciences, Pittsburgh, PA). Blots were then washed
extensively and immunoreactive proteins were visualized by using
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Oakville, ON) and by exposing the membrane to Amersham
Hyperfilm ECL (GE Healthcare Ltd. Buckinghamshire, UK). The
optical density of the immunoreactive bands for TrkB, BDNF and
GAPDH were quantified using ImageJ software. Density for TrkB
and BDNF was corrected for background and normalized to the
density of the corresponding band for GAPDH. The data were
expressed as a ratio of the optical densities of TrkB or BDNF to
GAPDH (whose expression was unaffected by treatment).
Quantitative Real Time PCR
Total RNA was isolated from mammary tumors (preserved in
RNAlater, Sigma Aldrich, St. Louis MO) using a Qiagen RNeasy
mini kit with on-column DNAse digestion (Qiagen, Mississauga,
ON) as per manufacturer instructions. Following confirmation of
RNA integrity by gel electrophoresis and quantification by
spectrophotometry, cDNA was reverse transcribed using random
primers (Invitrogen, Burlington, ON). Real time PCR was
performed with murine gene specific primers using an Applied
Biosystems 7900HT Fast Real Time PCR System (Applied
Biosystems, Foster City, CA). Gene- and species-specific primers
were designed for neurotrophins NGF, BDNF, NT-4/5 and
neurotrophin receptors TrkA, TrkB, TrkC, p75NTR using
OligoPerfect
TM (Invitrogen, Burlington ON) and ePCR software
(http://www.ncbi.nlm.nih.gov/sutils/e-pcr/reverse.cgi). Table S2
shows the sequence of the forward and reverse primers, amplicon
lengths, and accession numbers of the genes analyzed. Control
reactions without cDNA and a no RT control were run to verify the
absence of primer dimerization and genomic DNA contamination
respectively. PCR amplification was carried out in a 20 ml reaction
volume containing 5 ng of cDNA, 1.8 mM each of forward and
reverse primers, and 10 ml Fast SYBR Green Master Mix (Applied
Biosystems). The PCR reactions were initiated with denaturation at
95uC for 10 min; followed by 50 amplification cycles at 95uC for
15 s and 60uC for 1 min. Following amplification, to confirm the
presence of a single amplification product, PCR products were
subjected to a dissociation stage and derivative curve analysis as well
as product separation on a 4% agarose gel stained with ethidium
bromide. Samples were run in triplicate and results were averaged.
CT was calculated by anaysis software SDS 2.2.1 (Applied
Biosystems). Analysis of gene expression changes were calculated
according to the method of Livak et al. using the 2
2DDCT method
[50]. The normalized expression ratio (fold induction) was
calculated by 2
2DDCT=fold induction. Statistical analyses were
performed using the DCT6SD values.
Statistical Analysis
Statistical analysis was conducted using SigmaStat (SPSS Inc.,
Chicago, IL.). All data are reported as the mean6standard error
of the mean (SEM) unless otherwise noted. Treatment effects were
determined by one way analysis of variance (ANOVA) and
significant difference between the groups was determined by
pairwise multiple comparisons using Dunn’s test. Where the
normality test failed, data were compared by ANOVA on ranks.
The accepted level of statistical significance was set at p#0.05.
Supporting Information
Table S1 Breeding Data. Dams were treated daily for 5 days, 2
weeks prior to mating and then weekly dosing through weaning
with vehicle of 0.45, 2.25, and 4.5 mg dieldrin/g by gavage. Data
are the mean (6SD) and differences between treatment groups
were determined by one way ANOVA and appropriate post hoc
comparison test. *p,0.05 versus control.
Found at: doi:10.1371/journal.pone.0004303.s001 (0.04 MB
DOC)
Table S2 PCR primers
Found at: doi:10.1371/journal.pone.0004303.s002 (0.04 MB
DOC)
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